Investor Hub

We are a biotechnology company that promotes improved health globally through the discovery, development and commercialization of innovative vaccines to prevent serious infectious diseases.

Learn more

For much of my four-decade career, I’ve worked with biotech companies trying to solve significant health challenges, including HIV. Novavax is uniquely positioned to help end this pandemic with our protein-based vaccine. I believe in NVX-CoV2373 so much.
I came out of retirement to join the fight.

Lisa Dunkle

Vice President, Global Medical Lead for Coronavirus Vaccine

Governance documents

Get notifications for investor updates

Sign up for notifications from Novavax including upcoming events, webcasts, research updates, daily stock closings, SEC filings, and more.

Go to email subscription

Investor inquiries

Shareholders seeking information can contact investor relations at (240) 268-2022 or email us at [email protected]

Novavax corporate policy prohibits any employees, other than designated spokespersons, from communicating with its investors.

Investor Hub

Novavax, Inc. is a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases.

U.S. CDC and Advisory Committee Recommend Use of Authorized and Approved 2023-2024 Monovalent XBB COVID-19 Vaccines

Novavax Continues Progress Towards Delivery of its Protein-based Non-mRNA XBB COVID Vaccine to U.S.

Novavax Announces Grant of Inducement Awards Pursuant to Nasdaq Listing Rule 5635(c)(4)

Science & technology

Who we are

More information

Contact us

Careers